Should the amlodipine‑olmesartan (amlodipine and olmesartan) combination be continued in a patient with asymptomatic mottled, cold‑appearing skin who also takes over‑the‑counter multivitamins, a beet chew, and stopped omeprazole three months ago?

Discontinue Amlodipine/Olmesartan Immediately and Evaluate for Livedo Reticularis

The combination should be stopped immediately pending urgent evaluation of the mottled, cold-appearing skin, which may represent livedo reticularis—a potentially serious vascular phenomenon that can be associated with calcium channel blockers like amlodipine or indicate underlying systemic disease requiring immediate workup.

Critical Clinical Assessment Needed

The description of "asymptomatic mottled, cold-appearing skin" raises significant concern for:

• Livedo reticularis: A net-like vascular pattern that can be drug-induced (particularly by calcium channel blockers) or indicate serious underlying conditions including vasculitis, thrombotic disorders, or cholesterol emboli
• Peripheral vascular insufficiency: Cold extremities with mottling suggest compromised perfusion
• Systemic vasculopathy: Could represent atherosclerotic disease, autoimmune vasculitis, or hypercoagulable states

Immediate Actions Required

1. Physical examination specifics to document:

   • Exact distribution of mottling (extremities vs trunk)
   • Skin temperature differentials between affected and unaffected areas
   • Peripheral pulses (dorsalis pedis, posterior tibial, radial)
   • Capillary refill time
   • Presence of ulceration, necrosis, or digital ischemia
   • Whether pattern blanches with pressure

2. Urgent laboratory workup:

   • Complete blood count with differential
   • Comprehensive metabolic panel (renal function critical given ARB use)
   • Erythrocyte sedimentation rate and C-reactive protein
   • Antinuclear antibody, antiphospholipid antibodies if vasculitis suspected
   • Creatine kinase if considering statin-related myopathy with vascular effects

3. Consider vascular imaging if pulses diminished or asymmetric

Drug-Related Considerations

Amlodipine as Potential Culprit

Calcium channel blockers, particularly dihydropyridines like amlodipine, cause:

• Peripheral vasodilation that can paradoxically worsen perfusion in some vascular beds
• Dose-related peripheral edema (noted in 1 as more common in women)
• Rarely, livedo reticularis as an adverse effect

The 2-year duration of therapy doesn't exclude drug causation—adverse vascular effects can develop after prolonged exposure.

Olmesartan Considerations

While olmesartan itself is less likely to cause livedo reticularis, the FDA label 2 emphasizes monitoring for:

• Renal function deterioration (which could contribute to vascular complications)
• Electrolyte abnormalities
• Interaction risks with NSAIDs that could worsen renal perfusion

Alternative Antihypertensive Strategy

If hypertension control remains necessary after stopping amlodipine/olmesartan, consider:

Per 2017 ACC/AHA guidelines 1:

1. First-line alternatives without peripheral vascular effects:

   • Thiazide diuretics (chlorthalidone 12.5-25 mg preferred over hydrochlorothiazide due to longer half-life and proven CVD reduction)
   • ACE inhibitors (if no history of angioedema with ARBs; wait 6 weeks after stopping olmesartan per 2)
   • Beta-blockers if concurrent coronary disease or heart failure

2. Avoid:

   • Continuing any calcium channel blocker until vascular etiology clarified
   • Combination therapy until blood pressure reassessed off current medications

Medication Interaction Analysis

Current Supplements and Recent Medication Changes

• Multivitamins: Generally no significant interaction with antihypertensives
• Beet chew: Contains dietary nitrates that can lower blood pressure—may contribute to hypoperfusion if blood pressure drops excessively
• Omeprazole discontinuation 3 months ago: Previously, omeprazole could have increased amlodipine levels via CYP3A4 inhibition 3. Stopping omeprazole may have reduced amlodipine exposure, but this timing (3 months) makes acute withdrawal effects unlikely

The beet supplement warrants specific attention—dietary nitrate supplementation combined with antihypertensive therapy can cause excessive vasodilation and potentially contribute to the clinical picture.

Critical Pitfalls to Avoid

1. Don't assume "asymptomatic" means benign: Livedo reticularis can precede serious complications including tissue necrosis, stroke, or systemic thrombosis

2. Don't continue medications pending workup: The risk of progressive vascular compromise outweighs hypertension management for the brief period needed for evaluation

3. Don't attribute findings solely to medication without excluding serious systemic disease: Cholesterol emboli syndrome, antiphospholipid syndrome, and vasculitis require specific treatment beyond drug discontinuation

4. Don't restart calcium channel blockers if livedo resolves after stopping: This would confirm drug causation and risk recurrence

Blood Pressure Management During Evaluation

Monitor blood pressure closely after stopping combination therapy. Per 1, if blood pressure remains elevated:

• Short-term use of alternative agents (thiazide diuretic or ACE inhibitor) can be initiated
• Avoid combination therapy initially to isolate effects
• Target <130/80 mmHg per current guidelines, but prioritize vascular safety over immediate aggressive control

The occupational history (OSHA/safety director) suggests sedentary work with potential stress—lifestyle modifications including sodium restriction, weight management if applicable, and stress reduction should be emphasized during this transition period.